JP2015500822A5 - - Google Patents

Info

Publication number

JP2015500822A5

JP2015500822A5 JP2014545298A JP2014545298A JP2015500822A5 JP 2015500822 A5 JP2015500822 A5 JP 2015500822A5 JP 2014545298 A JP2014545298 A JP 2014545298A JP 2014545298 A JP2014545298 A JP 2014545298A JP 2015500822 A5 JP2015500822 A5 JP 2015500822A5

Authority

JP

Japan

Prior art keywords

immune complex

administered

dose

treatment cycle

approx

Prior art date

2012-12-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 claims 21
• 125000000539 amino acid group Chemical group 0.000 claims 12
• 239000012636 effector Substances 0.000 claims 9
• 239000008194 pharmaceutical composition Substances 0.000 claims 7
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 6
• 229960003957 dexamethasone Drugs 0.000 claims 6
• 229960004942 lenalidomide Drugs 0.000 claims 6
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
• 206010028980 Neoplasm Diseases 0.000 claims 5
• 229940127121 immunoconjugate Drugs 0.000 claims 5
• 231100000371 dose-limiting toxicity Toxicity 0.000 claims 4
• 229940127089 cytotoxic agent Drugs 0.000 claims 3
• 239000002254 cytotoxic agent Substances 0.000 claims 3
• 231100000599 cytotoxic agent Toxicity 0.000 claims 3
• 238000009115 maintenance therapy Methods 0.000 claims 3
• 238000002512 chemotherapy Methods 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 239000002552 dosage form Substances 0.000 claims 2
• 238000001794 hormone therapy Methods 0.000 claims 2
• 230000036039 immunity Effects 0.000 claims 2
• 231100000682 maximum tolerated dose Toxicity 0.000 claims 2
• 238000011269 treatment regimen Methods 0.000 claims 2
• 101150029707 ERBB2 gene Proteins 0.000 claims 1
• 102100038595 Estrogen receptor Human genes 0.000 claims 1
• 208000012766 Growth delay Diseases 0.000 claims 1
• 102100025803 Progesterone receptor Human genes 0.000 claims 1
• 238000011256 aggressive treatment Methods 0.000 claims 1
• 229960001716 benzalkonium Drugs 0.000 claims 1
• CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims 1
• 210000001124 body fluid Anatomy 0.000 claims 1
• 239000010839 body fluid Substances 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 108010038795 estrogen receptors Proteins 0.000 claims 1
• 238000009093 first-line therapy Methods 0.000 claims 1
• 229960000688 pomalidomide Drugs 0.000 claims 1
• UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
• 108090000468 progesterone receptors Proteins 0.000 claims 1
• 230000008685 targeting Effects 0.000 claims 1
• 238000011285 therapeutic regimen Methods 0.000 claims 1
• 230000004614 tumor growth Effects 0.000 claims 1